View Original / Current protocol | |
Registration number | |
Date of registration in ChiCTR | |
| Retrospective registration |
| 吉西他滨、左旋门冬酰胺酶、异环磷酰胺、地塞米松及足叶乙甙(GLIDE)方案治疗初发III/IV期及复发难治侵袭性NK/T细胞淋巴瘤的临床试验 |
| 吉西他滨、左旋门冬酰胺酶、异环磷酰胺、地塞米松及足叶乙甙(GLIDE)方案治疗初发III/IV期及复发难治侵袭性NK/T细胞淋巴瘤的临床试验 |
| |
Ethics approval status | |
Objectives of study | 评价GLIDE方案治疗初治的III/IV期和复发难治的侵袭性NK/T细胞淋巴瘤的有效性和安全性 |
Health condition(s) or problem(s) studied | 侵袭性NK/T细胞淋巴瘤(结外鼻型NK/T细胞淋巴瘤,侵袭性NK/T细胞白血病) |
| |
| |
| |
| |
| |
| 1、经病理组织学及免疫组织化学确诊的I/II期鼻型NK/T淋巴瘤患者。2、ECOG评分0-2分,无化疗禁忌症。3、预计生存期3个月以上。4、患者自愿参加并签署知情同意书。 |
| 1、妊娠妇女或正在哺乳期妇女;2、任何无法控制的临床问题(如严重的精神、神经、心血管、呼吸、活动性感染等系统疾病);3、已知对任何研究用药过敏的患者; |
| 治疗组: 吉西他滨 800mg/m^2 D1,8,左旋门冬酰胺酶 6000mg/m^2 D8,10,12,14,16,18,20,异环磷酰胺1g/m^2 D1-3,地塞米松40mg D1-4,D9-12(肠道淋巴瘤第一疗程给与强的松100mg D1-5),足叶乙甙 100mg/m^2 D1-3。总疗程6-8疗程。 |
| |
| 总生存期, 客观有效率, III-IV级毒性反应, 完全缓解率, |
| |
| |
Collecting sample(s) from participants | |
| |
| |
Anticipated date of the first enrolment | |
Anticipated date of the last enrolment | |
| |
| |
Countries of recruitment [Province(s) and city(s)] | |
Institution(s) or hospital(s) | |
Organizer institution (leader institution) | |
Institution responsible for collecting data | |
| |
Project number of funding source | |
| |
| |
| |
Date of application for trial registration | |
Contact person for public queries | |
Address of contact person | |
Phone No. of contact person | |
Postcode of contact person | |
Fax No. of contact person | |
Email of contact person | |
| |
Contact person for scientific queries | |
Address of the trial leader | |
Phone No. of the trial leader | |
Postcode of the trial leader | |
Fax No. of the trial leader | |
Email of the trial leader | |